USA
-
Curevo secures US$110M to advance promising shingles vaccine
Shingles, which occurs due to the reactivation of the varicella-zoster virus, can cause a painful rash and is especially common in adults over the age of 50.
-
BioArctic’s investigational MSA therapy gains FDA recognition
This designation is a significant milestone, as it provides incentives to encourage the development of treatments for rare diseases with high unmet medical needs.
-
Merck to close Pennsylvania antibiotics plant by 2026, layoffs planned
This closure represents the end of a significant era for the Cherokee site, which has been in operation since the 1950s.
-
Vivace Therapeutics secures US$35M to advance novel cancer drug
This funding will primarily support the clinical development of VT3989, an innovative cancer drug that targets the Hippo pathway by inhibiting the palmitoylation of TEAD proteins.
-
Mallinckrodt, Endo announce US$6.7B merger
Under the merger terms, Endo shareholders will receive US$80 million in cash and own 49.9% of the combined company, while Mallinckrodt shareholders will hold 50.1%.
-
Insilico Medicine raises US$110M to expand AI drug development
The funding will focus on advancing the clinical validation of Insilico’s flagship candidate, Rentosertib, which is designed to treat idiopathic pulmonary fibrosis (IPF).
-
-
-
-
